Infectious Vaccine Collaboration and Licensing Agreements Trends Analysis Report 2025 with Directory of 543 Deals Signed Since 2016 by Company A-Z, Therapy Focus and Technology Type


Dublin, Nov. 26, 2025 (GLOBE NEWSWIRE) -- The "Infectious Vaccine Collaboration and Licensing Deals 2016-2025" has been added to ResearchAndMarkets.com's offering.

This report contains a comprehensive listing of 543 infectious vaccine deals announced since 2016, including financial terms where available and links to online deal records of actual infectious vaccine partnering deals as disclosed by the deal parties.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Fully revised and updated, the report provides details of infectious vaccine deals from 2016 to 2025. The report provides a detailed understanding and analysis of how and why companies enter infectious vaccine deals. These deals tend to be multicomponent, starting with collaborative R&D and commercialization of outcomes.

The report includes collaboration, development, research, and licensing deals. Infectious Vaccine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the infectious vaccine deals entered into by the world's leading biopharma companies.

The initial chapters of this report offer an orientation to infectious vaccine dealmaking. Chapter 1 introduces the report, while Chapter 2 highlights trends in dealmaking since 2016. Chapter 3 reviews prominent deals based on headline value, and Chapter 4 identifies the top 25 companies active in the field, offering summaries and listings of available deals and contract documents. Chapters 5 and 6 explore the specifics of deals signed and announced since January 2016, focusing on public contract availability and specific technology types, respectively.

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in infectious vaccine dealmaking
2.1. Introduction
2.2. Infectious vaccine deals over the years
2.3. Most active infectious vaccine dealmakers
2.4. Infectious vaccine deals by deal type
2.5. Infectious vaccine deals by therapy area
2.6. Infectious vaccine deals by industry sector
2.7. Deal terms for infectious vaccine deals
2.7.1 Infectious vaccine deals headline values
2.7.2 Infectious vaccine deal upfront payments
2.7.3 Infectious vaccine deal milestone payments
2.7.4 Infectious vaccine royalty rates

Chapter 3 - Leading infectious vaccine deals
3.1. Introduction
3.2. Top infectious vaccine deals by value

Chapter 4 - Most active infectious vaccine dealmakers
4.1. Introduction
4.2. Most active infectious vaccine dealmakers
4.3. Most active infectious vaccine deals company profiles

Chapter 5 - Infectious vaccine contracts dealmaking directory
5.1. Introduction
5.2. Infectious vaccine contracts dealmaking directory

Chapter 6 - Infectious vaccine dealmaking by technology type

Deal directory
Deal directory - Infectious vaccine deals by company A-Z
Deal directory - Infectious vaccine deals by deal type
Deal directory - Infectious vaccine deals by therapy area
Deal type definitions

Companies Featured

  • Abera Bioscience
  • Aduro BioTech
  • Altimmune
  • Aurobindo Pharma
  • Bavarian Nordic
  • Bill and Melinda Gates Foundation
  • BioNet Holding
  • BioNTech
  • Biotechnology Industry Research Assistance Council
  • CanSinoBIO
  • Catalent
  • Centers for Disease Control and Prevention
  • Clover Biopharmaceuticals
  • Coalition for Epidemic Preparedness Innovations
  • CureVac
  • Defense Advanced Research Projects Agency
  • Department of Defense
  • Dyadic International
  • Emergent BioSolutions
  • eTheRNA immunotherapies
  • FluGen
  • Gilead Sciences
  • GlaxoSmithKline Biologicals
  • GSK
  • IDT Biologika
  • ImmunityBio
  • Indian Council of Medical Research
  • Infectious Disease Research Institute (IDRI)
  • International AIDS Vaccine Initiative
  • Janssen Pharmaceuticals
  • Medicago
  • Medigen Vaccine Biologics
  • Merck Sharpe & Dohme
  • Ministry of Health (Denmark)
  • Moderna
  • National Cancer Institute
  • National Institute of Infectious Diseases
  • Novavax
  • Oxford University
  • Pfizer
  • R-Pharm
  • Russian Direct Investment Fund
  • SaponiQx
  • Sanofi
  • Seqirus
  • Serum Institute of India
  • Sinovac Biotech
  • Takeda Pharmaceutical
  • University of Oxford
  • Valneva

For more information about this report visit https://www.researchandmarkets.com/r/hdeyft

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

 

Coordonnées

GlobeNewswire